A look at current literature and work by a statewide initiative can motivate development of policies that help respond to unrepresented patients’ needs.
AMA J Ethics. 2019;21(7):E611-616. doi:
10.1001/amajethics.2019.611.
When patients are unable to express their wishes and do not have surrogates or advance directives, which and whose values should inform decision making for them? We discuss ethical complexities of caring for unrepresented patients.
Claudia O. Gambrah-Sampaney, MD, Jesse E. Passman, MD, MPH, Andrielle Yost, MPA, and Glen N. Gaulton, PhD
In the past decade, more students than ever entered medical school with the desire, if not the expectation, of participating in meaningful global health experiences.
AMA J Ethics. 2019;21(9):E772-777. doi:
10.1001/amajethics.2019.772.
Michael Anderson, PhD and Susan Leigh Anderson, PhD
Two concerns (unknowability of how output is derived from input and overreliance on clinical decision support systems) are main sources of ethical questions about AI in health care.
AMA J Ethics. 2019;21(2):E125-130. doi:
10.1001/amajethics.2019.125.
Patrick S. Phelan, Mary C. Politi, PhD, and Christopher J. Dy, MD, MPH
During immediate and long-term recovery periods, decisions must account for patients’ personal goals and possible clinical outcomes and should clarify what recovery means.
AMA J Ethics. 2020;22(5):E380-387. doi:
10.1001/amajethics.2020.380.
How would gathering preclinical data and improving research infrastructure facilitate clearer definitions of “population vulnerability” and “risk acceptability”?
AMA J Ethics. 2020;22(1):E43-49. doi:
10.1001/amajethics.2020.43.